Human to pet in just one step.

Our proprietary PETization platform enables the rapid translation of therapeutic monoclonal antibodies (mAbs) between species.

Our mAbs are uniquely designed to be accepted by a patient's immune system as "native," a property we refer to as "100% species-specificity."

Our most advanced therapies in development are focused on treatments within two general areas: chronic pain in both dogs and cats, and inflammatory disease in dogs.

We believe biologic therapies offer significant advantages over current treatments in both these areas.

Our team of scientists and veterinarians are working to investigate further opportunities for new biologic therapies.

A diverse team of experts who are passionate about animal health.

Meet our team

Nexvet on tour

17-21 January 2015

North American Veterinary Community Conference, FL, U.S.

28 February - 7 March 2015

Veterinary Orthopedic Society of America Annual Conference, Sun Valley, ID, U.S.

2-5 April 2015

British Small Animal Veterinary Association Conference, Birmingham, U.K.

3–6 June 2015

American College of Veterinary Internal Medicine Forum, IN, U.S.

20-23 September 2015

Antibody Technologies and Therapeutics, Prato, Italy

Keep up with the transformation

Hear more — follow us on social media, browse extra content, and subscribe to our newsletter here.



16 April 2015

.@sciencemagazine Brace for dangerous levels of oxytocin. #upwardfacingdog #upwardfacingpug #pugchat

Register for Our Newsletter

Nexvet Biopharma

National Institute for Bioprocessing Research and Training 
Fosters Avenue, Mount Merrion
Blackrock, Co. Dublin
P: +353 (1) 215 8100

Level 8, 31 Queen Street
Melbourne 3000
P: +61 (3) 9610 4400

United States
Suite 2040
100 Pine Street
San Francisco, CA


Get in Touch